VIP is secreted by neurons in the esophagus where it relaxes the lower sphincter muscles, so we believe there is compelling evidence in favor of human clinical trials of anti-VIP or VIP receptor antagonist therapy to both reduce esophageal eosinophilia and improve esophageal motility dysfunction in EoE and even in GERD. This evidence concerns the gene VIP and gastroesophageal reflux disease.